

10/589474

Express Mail Label No. EV757867415US

JAPS Rec'd PCT/PTO 14 AUG 2006

Attorney Docket No. PB60727

---

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP2005/001449	10 February 2005	14 February 2004

---

TITLE OF INVENTION

MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY

---

APPLICANT(S) FOR DO/US

Ivan Leo PINTO, Shahzad Sharooq RAHMAN and Neville Hubert NICHOLSON

---

FILING OF AN INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

A copy of the International Search Report, which issued on International Application No. PCT/EP2005/001449 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

Copies of references not listed on the International Search Report are enclosed.

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

  
Grace C. Hsu  
Attorney for Applicants  
Registration No. 51,336

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-4650  
Facsimile (610) 270-5090

10/589474

IAPS Rec'd PCT/PTO 14 AUG 2006 Sheet 1 of 1

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60727	INTERNATIONAL APPLICATION NO. PCT/EP2005/001449
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Ivan Leo PINTO, Shahzad Sharooq RAHMAN and Neville Hubert NICHOLSON	
		FILING DATE Herewith	GROUP Unknown

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
------------------	--	-----------------	------	------	-------	----------	----------------------------

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation Yes   No
		EP 0 389 282	26 Sep 1990	EP			
		WO 92/09203	11 Jun 1992	WIPO			
		WO 93/16699	2 Sep 1993	WIPO			
		WO 99/20280	29 Apr 1999	WIPO			
		WO 02/084298	24 Oct 2002	WIPO			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Arch, Jonathan et al., "Inhibition of Type 4 Cyclic Nucleotide Phosphodiesterase by 8-Chloraxanthines" ARCHIV DER PHARMAZIE (Weinheim, Germany) 329(4), 1996, pp. 205-208 Coden: Arpmas; ISSN: 0365-6233, Compounds 2, 19.
	Jacobson, Kenneth et al., "Effect of Trifluoromethyl and Other Substituents on Activity of Xanthines at Adenosine Receptors", J. of Med. Chem., Vol. 36, No. (18), 1993, pp. 2639-44 Coden: JMCMAR; ISSN: 0022-2623, cited in the application, compound 28.
	Katsushima et al., "Structure-Activity Relationships of 8-Cycloalkyl_1, 3-Dipropylxanthines as Antagonists of Adenosine Receptors", J. of Med. Chem., American Chemical Society, Washington, DC, US, Vol. 33, July 1, 1990, pp. 1906-1910.
	Kattus, Albert A., et al., "Diuretic Activity of Compounds Related to Xanthines, Uracils, and Triazines as Determined in Dogs", Bulletin of the Johns Hopkins Hospital, 1951, 89, 1-8 Coden: JHHBAI; ISSN: 0097-1383.
	Smellie, F. W., et al., "Alkylxanthines: Inhibition of Adenosine-Elicited Accumulation of Cyclic AMP in Brain Slices and of Brain Phosphodiesterase Activity", 1979, Life Sciences, Vol. 24, No. 26, pp. 2475-81.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.